Compare Davita Inc (DVA) vs Nextpower Inc. Common Stock (NXT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nextpower Inc. Common Stock — how do they compare? Davita Inc trades at $180.7 (market cap $11.53B), while Nextpower Inc. Common Stock trades at $81 (market cap $12.53B). The key difference: Davita Inc and Nextpower Inc. Common Stock are close in size by market cap, and Davita Inc is trading nearer its 52-week high, Nextpower Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Nextpower Inc. Common Stock for 0 Days on average.
| DVA | NXT | |
|---|---|---|
Market Cap | $11.53B | $12.53B |
Volume | 444,368 | 3,195,746 |
Sector | Health | Energy |
52-Week High | $240.96 | $156.40 |
52-Week Low | $103.87 | $77.93 |
Typical Hold Time | 114 Days | 0 Days |
Enterprise Value | $24.25B | $11.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $182.08, up 0.17% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), revenue growth from $11.6B to $13.6B (2022-2025), and attractive valuation at P/E 15.43. Recent partnership expansion with Humana for value-based kidney care and institutional buying by BlackRock ($547.5M) support positive momentum. Operating cash flow remains robust at $1.89B (2025), though net cash flow turned negative due to debt repayments.
Outlook: DVA offers upside to consensus target ($235.67) with 29% potential, backed by earnings growth and strategic partnerships. Risks include high debt (debt-to-asset 65.55%), regulatory pressures, and margin volatility. Analyst consensus leans Hold (52.17%) amid balanced growth prospects and financial leverage concerns.
NXT trades at $88.77, up 4.61% today, with strong analyst support (86% buy ratings) and a $144.67 consensus price target suggesting 63% upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected November 16. Revenue grew from $3.0B in 2025 to $3.6B in 2026, while maintaining robust profitability with 16.36% net margins and 27.22% ROE.
Positive outlook driven by $5.5B+ backlog and raised 2027 guidance, though rising platform investment costs and solar sector volatility present risks. Technical levels show support at $86 with resistance at $91, while valuation multiples (P/E 22.94, P/S 3.76) appear reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nextpower Inc. Common Stock
Nextpower Inc., formerly known as Nextracker, is a solar energy technology company that designs tracking systems, structural foundations, and electrical balance-of-system equipment for utility-scale solar power plants. The company also develops software for solar yield management and is expanding into utility-scale power conversion systems.
Read more on NXT →
